Amicus Therapeutics, Inc.
1 Cedar Brook Drive
About Amicus Therapeutics, Inc.
Amicus Therapeutics is a global biotechnology company at the forefront of therapies for rare and orphan diseases. We have a unique set of platform technologies and medicines in development for people living with rare and devastating diseases, including the Lysosomal Storage Disorders Fabry disease and Pompe disease, as well as the genetic connective skin disorder Epidermolysis Bullosa (EB).
The needs of patients in the rare disease community are at the center of our inventive science, our commercial organization, and our clinical programs. Our goal throughout all levels of the organization is to make a meaningful difference in the lives of these patients and their caregivers.
321 articles with Amicus Therapeutics, Inc.
Amicus Therapeutics (Nasdaq: FOLD) today announced the official opening of the company’s Global Research and Gene Therapy Center of Excellence in uCity Square in Philadelphia to advance its industry leading portfolio of rare disease gene therapy programs
Amicus Therapeutics (Nasdaq: FOLD), a global, patient-dedicated biotechnology company focused on discovering, developing and delivering novel medicines for rare diseases, today announced financial results for the full-year ended December 31, 2019.
CRANBURY, N.J., Feb. 26, 2020 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that John F. Crowley, Chairman and Chief Executive Officer, will present at the Cowen & Company 40th Annual Health Care Conference in Boston, MA on Tuesday, March 3, 2020 at 8:40 a.m. ET. A live audio webcast of the presentation can also be accessed via the Investors section of the Amicus Therapeutics corporate website at http://ir.amicusrx.com/events-and-presentations , and will be ar
CRANBURY, N.J., Feb. 19, 2020 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Monday, March 2, 2020 at 8:30 a.m. ET to discuss financial results for the full year ended December 31, 2019. The call will be led by John F. Crowley, Chairman and Chief Executive Officer. He will be joined on the call by additional members of the Amicus senior leadership team. Interested participants and investors may acc
CRANBURY, N.J., Feb. 07, 2020 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), a global, patient centric biotechnology company focused on discovering, developing and delivering novel medicines for rare diseases, today announced that one oral presentation and nine posters highlighting its development programs for Lysosomal Disorders will be included at the 16th Annual WORLD Symposium ™ 2020 , to be held February 10-13, 2020 in Orlando, FL. Oral Platform Presentations: Ba
Amicus Therapeutics, a global, patient centric biotechnology company focused on discovering, developing and delivering novel medicines for rare diseases, provided its full-year 2020 strategic outlook and financial guidance.
Amicus Therapeutics Announces Preliminary 2019 Galafold Revenue - Exceeding Upper End of Prior Guidance
Galafold Revenue of $181 Million for Full-Year 2019 and $54 Million in Q4 Reflects Continued Strong Adoption & Patient Adherence in All Key Global Regions
Amicus Therapeutics Provides Updates on Clinical, Regulatory and Manufacturing Advancements for AT-GAA for Pompe Disease
Company Plans to Apply for and Initiate a Rolling Biologics License Application (BLA) for AT-GAA in 2020 with Addition of Full Clinical Results in 1H2021 to Support Full Approval under Fast Track Designation
Amicus Therapeutics (Nasdaq: FOLD), a global biotechnology company focused on discovering, developing and delivering novel medicines for rare metabolic diseases, today announced financial results for the third quarter ended September 30, 2019.
Amicus Therapeutics announced that the Company will host a conference call and live audio webcast on Monday, November 11, 2019 at 8:30 a.m. ET to discuss financial results for the third quarter ended September 30, 2019.
Amicus Announces Additional Positive Interim Clinical Data for CLN6 Batten Disease Gene Therapy at 48th Annual Meeting of the Child Neurology Society
Amicus Therapeutics announced additional positive interim results from its CLN6 Batten disease gene therapy program licensed from the Abigail Wexner Research Institute at Nationwide Children’s Hospital.
Amicus Therapeutics Announces Preliminary Third Quarter 2019 Revenue and Financial Outlook at 2019 Analyst Day
Analyst Day 2019 to Highlight Financial Outlook and Robust Portfolio of Novel Therapies for Rare Metabolic Diseases
Every week brings news of clinical trials, ranging from launches, first-patient dosing, full enrollment, interim data or final data. Here’s a look at some of the clinical trial news from last week.
Amicus Therapeutics' Gene Therapy for Rare, Fatal Childhood Disease Shows Promise in Early Clinic...
8/2/2019Amicus Therapeutics announced positive interim results from its CLN6 Batten disease gene therapy program. Batten disease is a fatal neurologic illness that results in children losing the ability to walk, speak, think and see.
Under the agreement, Thermo Fisher will provide Amicus with immediate clinical and commercial manufacturing capabilities and capacity for Amicus’ intrathecal AAV Batten disease gene therapy programs.
The deal broadens their work together from three to six programs for rare genetic diseases, as well as rights to collaborative R&D of novel gene therapies for lysosomal disorders and 12 additional rare diseases.
4/18/2019In the first quarter of 2019, more than 30 life science companies* announced expansions, new locations, increased funding, new trial and product launches and various other news pointing to a growing industry.
Amicus Therapeutics, headquartered in Cranbury, New Jersey, announced it is launching a Global Research and Gene Therapy Center of Excellence in Philadelphia.
WuXi Biologics ("WuXi Bio") (2269.HK), development and manufacturing, and Amicus Therapeutics ("Amicus") (Nasdaq: FOLD), a global, patient-dedicated biotechnology company focused on discovering, developing and delivering high-quality medicines for people living with rare metabolic diseases, announced that the companies have entered into an exclusive commercial manufacturing partnership for Amicus' Pompe biologic ATB200.
Over the course of 2018, the FDA approved 59 different novel drugs that range for the treatment of various cancers, chronic obstructive pulmonary disease (COPD), traveler’s diarrhea, migraine headaches and more.